AOCNP Immunotherapy and Targeted Therapy

Question 1

Which class of immunotherapy works by blocking the PD-1/PD-L1 checkpoint pathway to restore anti-tumor T-cell activity?

Accepted Answer

Checkpoint inhibitors

Answer

CAR-T cell therapy

Answer

Monoclonal antibodies targeting HER2

Answer

Cytotoxic T-lymphocyte vaccines

Question 2

Imatinib (Gleevec) is a tyrosine kinase inhibitor (TKI) that targets which molecular abnormality in chronic myelogenous leukemia (CML)?

Accepted Answer

BCR-ABL fusion protein

Answer

EGFR mutation

Answer

HER2 amplification

Answer

ALK rearrangement

Question 3

A patient receiving pembrolizumab develops severe, grade 3 immune-related pneumonitis. What is the most appropriate initial management?

Accepted Answer

Permanently discontinue pembrolizumab and start high-dose corticosteroids

Answer

Continue pembrolizumab at reduced dose

Answer

Hold pembrolizumab and begin inhaled corticosteroids

Answer

Switch to a different checkpoint inhibitor

Question 4

Which biomarker must be tested before initiating trastuzumab (Herceptin) therapy for breast cancer?

Accepted Answer

HER2 overexpression or gene amplification

Answer

KRAS mutation status

Answer

EGFR mutation

Answer

PD-L1 expression level

Question 5

Cytokine release syndrome (CRS) is a potentially life-threatening toxicity most commonly associated with which type of immunotherapy?

Accepted Answer

CAR-T cell therapy and bispecific T-cell engagers

Answer

PD-1 checkpoint inhibitors

Answer

Anti-VEGF monoclonal antibodies

Answer

PARP inhibitors

Question 6

EGFR-mutated non-small cell lung cancer (NSCLC) is most effectively treated with which class of targeted agents?

Accepted Answer

EGFR tyrosine kinase inhibitors (e.g., osimertinib)

Answer

VEGF inhibitors (bevacizumab)

Answer

ALK inhibitors (e.g., crizotinib)

Answer

KRAS G12C inhibitors (e.g., sotorasib)